[Change of cytokines and clinical efficacy of panipenem/betamipron in obstetric and gynecological infections. Yamagata Study Group of Panipenem/Betamipron in Obstetric and Gynecological Infections].
Efficacy and safety of panipenem/betamipron (PAPM/BP) in treatment of obstetric and gynecological infections, and change of interleukin-6 (IL-6) and interleukin-8 (IL-8) levels in blood, as markers of infection, were investigated. The results were as follows; 1) Clinical efficacy of PAPM/BP by drip infusion of 1-2 g/day for 3-14 days against 52 patients with intrauterine infection (n = 29), pelveoperitonitis (n = 19), and other infections were 14 "Excellent" in 14 cases, "Good" in 35 cases, and efficacy rate was 94.2% (49/52). Both efficacy rate analy by causative organisms and eradication rate were 35/37 (94.6%). No subjective or objective side effects and no abnormal labolatory findings were observed. 2) Changes of IL-6 (> 4 pg/ml) levels in serum, as an infection marker, were observed in 8 cases out of 14 cases (57.1%), and correlation between CRP and IL-6 in the treatment process was noticed. However, changes of serum IL-8 (> 12.5 pg/ml) were observed in only 2 cases of those 14 cases (14.3%), indicative that IL-8 has no significance as a marker of infection.
Chimura
T
T
Department of Obstetrics and Gynecology, Shirataka Hospital.
Oda
T
T
Saito
N
N
Morisaki
N
N
Numasaki
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000097:blood* / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005831:Genital Diseases, Female / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D016209:Interleukin-8 / Q000097:blood*; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000097:blood / Q000188:drug therapy; D010538:Peritonitis / Q000097:blood / Q000188:drug therapy; D013845:Thienamycins / Q000008:administration & dosage / Q000627:therapeutic use; D014591:Uterine Diseases / Q000097:blood / Q000188:drug therapy; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D015415:Biomarkers; D015850:Interleukin-6; D016209:Interleukin-8; D013845:Thienamycins; D015091:beta-Alanine; C075316:panipenem-betamipron